Updated:
GeoVax Labs, Inc.
GeoVax Labs, Inc. (GOVX) is a publicly traded biotech developing vaccines for infectious diseases and cancers, with no disclosed investment portfolio.
GeoVax Labs, Inc.
GeoVax Labs, Inc. operates as a publicly traded biotechnology firm (NASDAQ: GOVX) that develops vaccines and immunotherapies. Its founding traces to the early 2000s, emerging from Georgia-based research. The company's pipeline includes programs for COVID-19, HIV, and various cancers. GeoVax employs a proprietary Modified Vaccinia Ankara (MVA) viral vector platform to generate immune responses. It has no disclosed assets, deployment, or portfolio in the traditional investment sense — its activity is research and development. The firm partners with academic institutions and government agencies for funding and trials, but does not function as an asset manager or family office. No team size, additional offices, or philanthropic vehicles were confirmed. Recent activity includes March 2025: GeoVax announced a licensed patent agreement with a research institute for its malaria vaccine candidate (per SEC filings, 2025). GeoVax's structural differentiator is its public company status and focus on preclinical and clinical vaccine R&D, positioning it as a biotech equity rather than an investment entity.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Does GeoVax Labs operate as a family office or investment firm?
No. GeoVax Labs is a publicly traded biotechnology company (NASDAQ: GOVX) that develops vaccines and immunotherapies. It does not manage assets for families or external investors.
What is GeoVax Labs' primary business?
It is a clinical-stage biotech using its MVA viral vector platform to create vaccines for COVID-19, HIV, and cancers. Its revenue comes from grants, partnerships, and equity raises, not investment returns.
Does GeoVax Labs make direct investments or back external funds?
No. GeoVax is not an investment firm. It focuses on research and development of vaccine candidates, with no publicly disclosed investment portfolio or fund commitments.
Who leads GeoVax Labs?
As of 2025, David Dodd serves as CEO and Chairman (per SEC filings). The company's management team includes scientific and operational executives, not investment professionals.
What is the source of GeoVax Labs' funding?
GeoVax raises capital through public equity offerings, government grants (e.g., from the U.S. National Institutes of Health), and collaborative agreements. It does not manage an externally invested fund.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: